2m 2m 2m 2m 2m 2m 2m
Nunzia Pharma-A (NUNZ)
OTC
$0.0001$0.00 (0.00%)
Price as of Jan 21, 2026- $43,451.00Market Cap
- 9,900.00%1-Year Change
- Drug Manufacturers - Specialty & GenericIndustry
Nunzia Pharma-A (NUNZ)
$0.0001$0.00 (0.00%)
Annual
Quarterly
12/31/2021 | 12/31/2020 | ||
|---|---|---|---|
Income Statement | |||
Total Operating Revenue | 0 N/A | 0 N/A | |
Cost of Revenue | N/A N/A | N/A N/A | |
Gross Profit | 0 N/A | 0 N/A | |
Sales and Marketing Expense | N/A N/A | 29,835 N/A | |
Research and Development Expense | N/A N/A | N/A N/A | |
Depreciation and Amortization Expense | N/A N/A | N/A N/A | |
Total Operating Expenses | 78.1M +198,391.90% | 39,327 N/A | |
Operating Profit | -78.1M +198,391.90% | -39,327 N/A | |
Interest Income | N/A N/A | N/A N/A | |
Interest Expense | N/A N/A | N/A N/A | |
Interest Income and Expense and Net | 0 N/A | 0 N/A | |
Total Nonoperating Income and Expense | -1,862 -100.00% | -101.0M N/A | |
Income before Taxes | -78.1M +198,391.90% | -39,327 N/A | |
Income Taxes | 0 N/A | 0 N/A | |
Extraordinary Items | N/A N/A | N/A N/A | |
Net Income | -78.1M -22.72% | -101.0M N/A | |
Net Income from Continuing Operations Applicable to Common | -78.1M -22.72% | -101.0M N/A | |
Basic EPS and Net Income | -0.26 -25.71% | -0.35 N/A | |
Diluted EPS and Net Income | -0.26 -25.71% | -0.35 N/A | |
Basic Weighted Average Shares | 305.4M +7.19% | 284.9M N/A | |
Diluted Weighted Average Shares | 305.4M +7.19% | 284.9M N/A | |
Balance Sheet | |||
Cash and Cash Equivalents | 131 N/A | 0 N/A | |
Short-Term Investments | N/A N/A | N/A N/A | |
Cash and Cash Equivalents and Short-Term Investments | 131 N/A | 0 N/A | |
Total Current Assets | 131 N/A | 0 N/A | |
Accumulated Depreciation | N/A N/A | N/A N/A | |
Property and Plant and Equipment and Net | N/A N/A | N/A N/A | |
Total Long-Term Assets | N/A N/A | N/A N/A | |
Total Assets | 5,131 N/A | 0 N/A | |
Income Taxes Payable | N/A N/A | N/A N/A | |
Total Short-Term Debt | 97,443 +824.86% | 10,536 N/A | |
Total Current Liabilities | 99,305 +172.79% | 36,404 N/A | |
Total Long-Term Debt | 0 -100.00% | 23,000 N/A | |
Total Long-Term Liabilities | 0 N/A | N/A N/A | |
Total Liabilities | 99,305 +67.17% | 59,404 N/A | |
Retained Earnings | -179.4M +77.02% | -101.4M N/A | |
Total Stockholders Equity | -94,174 +58.53% | -59,404 N/A | |
Total Shares Outstanding | 434.2M +77.63% | 244.4M N/A | |
Cash Flow | |||
Cash from Operating Activities | -86,776 +277.29% | -23,000 N/A | |
Capital Expenditures | N/A N/A | N/A N/A | |
Cash from Investing Activities | N/A N/A | N/A N/A | |
Dividends Paid | N/A N/A | N/A N/A | |
Cash from Financing Activities | 86,907 +277.86% | 23,000 N/A | |
Financials Ratio | |||
Gross Margin | N/A N/A | N/A N/A | |
Operating Margin | N/A N/A | N/A N/A | |
Return on Assets | -3,042,789.71% N/A | N/A N/A | |
Return on Equity | 101,658.79% N/A | N/A N/A | |
Revenue Growth | N/A N/A | N/A N/A | |
Current Ratio | 0.001 N/A | N/A N/A | |
Cash Ratio | 0.001 N/A | N/A N/A | |
Debt-to-Equity Ratio | -1.03 N/A | N/A N/A | |
Debt-to-Assets Ratio | 18.99 N/A | N/A N/A | |
Earnings & Revenue History
Debt-to-Assets
Cash Flow